|
|
 |
|
Viewing report
|
|
|
|
Endometrial Cancer Therapeutics - Pipeline Assessment and Market Forecasts to 2017
GlobalData, March 2011, Pages: 102
Endometrial Cancer Therapeutics - Pipeline Assessment and Market Forecasts to 2017
Summary
GlobalData, the industry analysis specialist, has released its new report, “Endometrial Cancer Therapeutics - Pipeline Assessment and Market Forecasts to 2017”. The report is an essential source of information and analysis on the global endometrial cancer therapeutics market. The report identifies the key trends shaping and driving the global endometrial cancer market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global endometrial cancer sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.
GlobalData estimated has estimated the global endometrial cancer market to be valued at $137 m in 2010. It is expected to grow to $179 m with a Compound Annual Growth Rate (CAGR) of 3.91% by 2017. This growth is primarily attributed to the increasing prevalence of the disease due to the aging population, diabetes and obesity. The diagnosis and treatment seeking rate is also high in endometrial cancer. Currently there are no approved drugs for endometrial cancer and the market will be driven by the expected launch of the Ixempra (ixabepilone) in 2015.
Scope
The report provides information on the key drivers and challenges of the endometrial cancer therapeutics market. Its scope includes -
- Annualized seven key markets (The US, France, Germany, Italy, Spain, The UK and Japan) endometrial cancer market revenues data from 2005 to 2009, forecast for eight years to 2017.
- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under the following mechanism of action which are LHRH antagonists, mTOR inhibitor, angiogenesis inhibitor, VEGF inhibitor, TK inhibitor and DNA Repair Suppressor, AKT/PKB inhibitor, LH/hCG targeter, MEK inhibitor and AKT kinase inhibitor, steroid sulphatase inhibitor, tubulin-binding agent, beta-catenin targeter, mTOR kinase inhibitor and AKT inhibitor, triple angiokinase inhibitor and cytotoxic agent
- Analysis of the current and future competition in the seven key countries endometrial cancer market. Key market players covered are AEterna Zentaris, Bristol-Myers Squibb Company, Eisai Co., EntreMed, Novartis AG, and PharmaMar,
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the endometrial cancer therapeutics market.
- Analysis of key recent licensing and partnership agreements in endometrial cancer market
Reasons to buy
The report will enhance your decision making capability. It will allow you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global endometrial cancer market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global endometrial cancer market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What’s the next big thing in the global endometrial cancer market landscape? – Identify, understand and capitalize.
|
|
|
|
